The Federal Trade Commission is challenging hundreds of pharmaceutical patent listings in an effort to smooth the path to more affordable alternatives to brand-name drugs—including blockbusters ...
The antitrust cop says that the more than 300 patent listings stall generic competition, keeping prices high for diabetes drugs, inhalers and more. The Federal Trade Commission is challenging ...
The Federal Trade Commission is stepping up its crackdown on so-called "junk patents," which it contends are ploys intended ...
The U.S. Federal Trade Commission (FTC) is not done with its crackdown on what it views as improper listing of patents with the FDA. After an initial round of challenges launched in November ...
What Happened: The FTC is disputing “junk patent listings” for diabetes, weight loss, asthma and COPD drugs. This initiative represents the latest endeavor against what the ag ...
The Orange Book is a critical tool for drugmakers because they can sue a generic developer who applies for approval of a product with a listed patent, blocking the entry of a copycat medicine for 30 ...
The U.S. Federal Trade Commission expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings pertaining to 20 different brand-name treatments for ...
The USA’s Federal Trade Commission yesterday revealed it has expanded its campaign against pharmaceutical manufacturers’ improper or inaccurate listing of patents in the Food and Drug Administration’s ...